Effect of Incretin-related Drugs on Dietary Intake in Japanese Patients With Type 2 Diabetes Mellitus
Recruitment status was: Active, not recruiting
It is well known that incretin, particular GLP-１enhances satiety and reduces energy intake in controlling appetite and dietary in humans (Flint A, et al. Gutzwiller JP et al.). Recently, incretin-based therapy has been attracted a lot of interest (Hare KJ, Knop FK). However, it is not clear how the incretin-based therapy affects energy and content of dietary intake in patients with type 2 diabetes mellitus (T2DM). Previously, the investigators reported the amount of energy and content of dietary intake in type 2 diabetic Japanese patients with more than 10 years of long time duration after discovery using questionnaire (Inoue K et al.) and the patients were impaired a secretion of active GLP-1 (Kamoi et al).
The investigators examine whether the incretin-based therapy effects on the energy and content of dietary intake in the same patients before and one year after administration of incretin-related drugs using the same method previously (Inoue K et al.).
|Study Design:||Observational Model: Cohort
Time Perspective: Prospective
|Official Title:||Effect of Incretin-related Drugs on Energy and Contents of Dietary Intake in Japanese Patients With Type 2 Diabetes Mellitus|
- HbA1c [ Time Frame: one year ] [ Designated as safety issue: Yes ]
- BMI [ Time Frame: One year ] [ Designated as safety issue: Yes ]
- Calory of dietary intake [ Time Frame: One year ] [ Designated as safety issue: Yes ]
- Content of dietary intake [ Time Frame: One year ] [ Designated as safety issue: Yes ]
|Study Start Date:||January 2010|
|Estimated Study Completion Date:||January 2014|
|Estimated Primary Completion Date:||January 2014 (Final data collection date for primary outcome measure)|
Drug: Incretin-related drugs
DPP-IV inhibitors are administered via per os. GLP-L receptor agonists are administered via subcutaneous injections.
Other Name: If necessary, other hypoglycemic and insulin drugs
Please refer to this study by its ClinicalTrials.gov identifier: NCT01568125
|Nagaoka Red Cross Hospital|
|Nagaoka, Niigata, Japan, 940-2085|
|Principal Investigator:||Kyuzi Kamoi, MD||Nagaoka Red Cross Hospital|
|Principal Investigator:||Yoshiko Kontai, RD||Universty of Niigata Prefecture|
|Principal Investigator:||Kanako Inoue, RD||Universty of Niigata Prefecture|